Loading...

Stereotaxis, Inc.

STXSAMEX
Healthcare
Medical - Instruments & Supplies
$1.73
$-0.05(-2.81%)
U.S. Market opens in 13h 45m

Stereotaxis, Inc. Fundamental Analysis

Stereotaxis, Inc. (STXS) shows moderate financial fundamentals with a PE ratio of -7.91, profit margin of -69.50%, and ROE of -1.53%. The company generates $0.0B in annual revenue with strong year-over-year growth of 20.28%.

Key Strengths

PEG Ratio-0.30
Current Ratio1.55

Areas of Concern

ROE-1.53%
Operating Margin-68.49%
We analyze STXS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -160.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-160.5/100

We analyze STXS's fundamental strength across five key dimensions:

Efficiency Score

Weak

STXS struggles to generate sufficient returns from assets.

ROA > 10%
-40.13%

Valuation Score

Excellent

STXS trades at attractive valuation levels.

PE < 25
-7.91
PEG Ratio < 2
-0.30

Growth Score

Excellent

STXS delivers strong and consistent growth momentum.

Revenue Growth > 5%
20.28%
EPS Growth > 10%
16.67%

Financial Health Score

Excellent

STXS maintains a strong and stable balance sheet.

Debt/Equity < 1
0.27
Current Ratio > 1
1.55

Profitability Score

Weak

STXS struggles to sustain strong margins.

ROE > 15%
-153.21%
Net Margin ≥ 15%
-69.50%
Positive Free Cash Flow
No

Key Financial Metrics

Is STXS Expensive or Cheap?

P/E Ratio

STXS trades at -7.91 times earnings. This suggests potential undervaluation.

-7.91

PEG Ratio

When adjusting for growth, STXS's PEG of -0.30 indicates potential undervaluation.

-0.30

Price to Book

The market values Stereotaxis, Inc. at 8.75 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

8.75

EV/EBITDA

Enterprise value stands at -9.16 times EBITDA. This is generally considered low.

-9.16

How Well Does STXS Make Money?

Net Profit Margin

For every $100 in sales, Stereotaxis, Inc. keeps $-69.50 as profit after all expenses.

-69.50%

Operating Margin

Core operations generate -68.49 in profit for every $100 in revenue, before interest and taxes.

-68.49%

ROE

Management delivers $-1.53 in profit for every $100 of shareholder equity.

-1.53%

ROA

Stereotaxis, Inc. generates $-40.13 in profit for every $100 in assets, demonstrating efficient asset deployment.

-40.13%

Following the Money - Real Cash Generation

Operating Cash Flow

Stereotaxis, Inc. generates limited operating cash flow of $-15.17M, signaling weaker underlying cash strength.

$-15.17M

Free Cash Flow

Stereotaxis, Inc. generates weak or negative free cash flow of $-15.34M, restricting financial flexibility.

$-15.34M

FCF Per Share

Each share generates $-0.16 in free cash annually.

$-0.16

FCF Yield

STXS converts -9.21% of its market value into free cash.

-9.21%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-7.91

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.30

vs 25 benchmark

P/B Ratio

Price to book value ratio

8.75

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.44

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.27

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.55

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.53

vs 25 benchmark

ROA

Return on assets percentage

-0.40

vs 25 benchmark

ROCE

Return on capital employed

-0.69

vs 25 benchmark

How STXS Stacks Against Its Sector Peers

MetricSTXS ValueSector AveragePerformance
P/E Ratio-7.9128.65 Better (Cheaper)
ROE-153.21%795.00% Weak
Net Margin-69.50%-49787.00% (disorted) Weak
Debt/Equity0.270.40 Strong (Low Leverage)
Current Ratio1.553.73 Neutral
ROA-40.13%-20255.00% (disorted) Weak

STXS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Stereotaxis, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-2.76%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-160.44%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-211.67%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ